Senolytic and senomorphic therapies, including Rubedo’s RLS-1496 in Phase 1 trials, target senescent cells to treat aging diseases, boosted by AI-driven discovery and rising investment. New seno...
Recent breakthroughs in senolytic and senomorphic therapies, including polyunsaturated lipids inducing ferroptosis, are advancing clinical trials for age-related diseases, with a focus on safety and b...
Recent UK Biobank data reveals myostatin variants boosting muscle mass, with research accelerating on combining inhibitors with GLP-1 drugs to combat sarcopenia, highlighting ethical debates in therap...
Exploring recent advances in senolytic and senomorphic therapies, including dasatinib-quercetin and immune-based approaches, to combat age-related diseases like Alzheimer’s and sarcopenia. New t...
Recent studies reveal that supplementing Roseburia inulinivorans enhances muscle strength by up to 30% in mice, with human trials showing promise for probiotic therapies against sarcopenia. New resear...
Recent studies show Roseburia inulinivorans boosts muscle strength in aging, with probiotics targeting sarcopenia gaining traction in the wellness market amid regulatory and ethical debates. Breakthro...
7-ketocholesterol (7KC), an oxidized cholesterol, is linked to cardiovascular and neurodegenerative diseases, with recent AI diagnostics and clinical trials advancing preventive healthcare for aging p...
ARPA-H’s PROSPR program directs over $50 million to aging trials, advancing drugs like Cambrian’s rapamycin analog and Linnaeus’s GPER-targeter, signaling a shift in treating aging a...
Recent research reveals that depleting gut microbiota in aged mice improves brain structure and function, highlighting the gut-brain axis as a key target for anti-aging therapies. Manipulating gut mic...
Recent advancements in cellular reprogramming, including significant funding and clinical trials, are transforming anti-aging science by targeting root causes of age-related diseases. Cellular reprogr...
